Japan’s Peptide Door Receives ¥750 Million Investment From Tohoku Innovation Capital
This article was originally published in PharmAsia News
Executive Summary
Sentai, Japan-based Tohoku Innovation Capital has invested ¥750 million in Peptide Door Co., a biopharmaceutical venture company based in Takasaki, Japan, with core technology related to therapeutic peptides. Peptides allow the creation of peptide antibodies in animals without the need to purify the protein of interest, and it has received increasing attention from drug developers. Peptide Door currently is conducting joint research on a treatment for septicemia with other pharmaceutical companies. (Click here for more - Japanese language
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.